Reliable Biopharmaceutical Corporation announces submission of its Drug Master File for Fondaparinux Sodium (Fonda) to the U.S. FDA
Reliable Biopharmaceutical Corporation (RBC) announced today that they filed a Drug Master File (DMF) with the U.S. FDA for Fondaparinux Sodium active pharmaceutical ingredient (API) on June 30, 2011.
The current global market size for Fondaparinux is $475.5 Million growing at 15% (as reported by IMS Health). Mr. David Feldker, President and CEO, Reliable Biopharmaceutical Corporation said, “I am very proud of our multi-year effort to complete the Fondaparinux development using our proprietary process which will differentiate RBC from the competition. This is a significant accomplishment for RBC and demonstrates our commitment to produce low cost, high quality API’s for the generic drug market.”
About Reliable Biopharmaceutical Corporation
Founded in 1968, RBC is an integrated developer and manufacturer of active pharmaceutical ingredients ("APIs") and High Purity Ingredients ("HPIs") for pharmaceuticals and biologics. RBC has established a strong position as a leading developer and manufacturer of complex generic injectable APIs. The Company has developed 19 generic injectable APIs to date that have been accepted as Type II Drug Master Files by the FDA and has 19 more in various stages of development. RBC's products are the active ingredients for leading generic injectable drugs that treat cancer, heart disease, hypertension, anxiety and other serious and life threatening illnesses. RBC also manufactures critical processing aids for the pharmaceutical industry and currently supplies these products to many of the world's leading pharmaceutical and biotechnology companies. RBC is a portfolio company of Med Opportunity Partners, LLC.
About Med Opportunity Partners, LLC
Med Opportunity Partners, LLC (http://www.MedOpportunity.com) is a Greenwich, CT- based operating oriented private equity firm that acquires leading healthcare companies at their growth stage. MEDOP is dedicated to investing in companies that drive healthcare innovation, growth and consolidation. Founded by seasoned healthcare investors and operators, MEDOP partners with companies that can benefit from its extensive industry knowledge, relationships and proven operating and transaction experience. MEDOP receives funding from prominent investors including pension funds, endowments, insurance companies, and private families.
For more information, contact:
Reliable Biopharmaceutical Corporation
James Wickenhauser, Vice President Sales and Marketing
1945 Walton Road
St. Louis, MO 63114